{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T18:27:06Z","timestamp":1776709626739,"version":"3.51.2"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T00:00:00Z","timestamp":1680480000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Med Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The objective of this study was to investigate whether the albumin-to-fibrinogen ratio (AFR) can predict corticosteroid response and prognosis prediction among IgA nephropathy (IgAN) patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Eligible participants with diagnosed IgAN who were scheduled to receive corticosteroid therapy for persistent proteinuria were recruited. Receiver operating characteristic (ROC) curve analysis was performed to evaluate the predictive value of AFR or estimated glomerular filtration rate (eGFR) for corticosteroid response in IgAN patients. Risk factors for corticosteroid response and prognosis were validated using univariate and multivariate Cox proportional analyses.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>AFR and eGFR were both effective predictors of corticosteroid response in IgAN patients, with area under the curve (AUC) values of 0.686 and 0.643, respectively (<jats:italic>P<\/jats:italic>\u2009&lt;\u20090.001 and <jats:italic>P<\/jats:italic>\u2009=\u20090.002). Baseline AFR level at biopsy was an independent risk factor for remission after corticosteroid therapy (HR: 2.38, 95% CI 1.32\u20134.07, <jats:italic>P<\/jats:italic>\u2009=\u20090.015), 50% decline in eGFR (HR: 0.78, 95% CI 0.69\u20130.89, <jats:italic>P<\/jats:italic>\u2009=\u20090.025), kidney failure (HR: 2.46, 95%CI 1.16\u20133.71, <jats:italic>P<\/jats:italic>\u2009=\u20090.016), and a composite event (HR: 2.13, 95%CI 1.28\u20133.34, <jats:italic>P<\/jats:italic>\u2009=\u20090.009) in IgAN patients.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>AFR level at biopsy was a potential predictor of corticosteroid response and prognosis among IgAN patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s40001-023-01106-6","type":"journal-article","created":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:33:49Z","timestamp":1680518029000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Albumin-to-fibrinogen ratio is an independent predictor of corticosteroid response and prognosis in patients with IgA nephropathy"],"prefix":"10.1186","volume":"28","author":[{"given":"Yu","family":"Zhang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liping","family":"Man","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,4,3]]},"reference":[{"issue":"4","key":"1106_CR1","doi-asserted-by":"publisher","first-page":"677","DOI":"10.2215\/CJN.07420716","volume":"12","author":"JC Rodrigues","year":"2017","unstructured":"Rodrigues JC, Haas M, Reich HN. IgA Nephropathy. Clin J Am Soc Nephrol. 2017;12(4):677\u201386.","journal-title":"Clin J Am Soc Nephrol"},{"key":"1106_CR2","doi-asserted-by":"publisher","first-page":"105678","DOI":"10.1016\/j.intimp.2019.105678","volume":"74","author":"H Yang","year":"2019","unstructured":"Yang H, Zhang W, Li Y, Li R. Neutrophil-to-lymphocyte ratio: An effective predictor of corticosteroid response in IgA nephropathy. Int Immunopharmacol. 2019;74:105678.","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"1106_CR3","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/S0272-6386(00)70316-7","volume":"35","author":"P Maisonneuve","year":"2000","unstructured":"Maisonneuve P, Agodoa L, Gellert R, Stewart JH, Buccianti G, Lowenfels AB, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia\/New Zealand: results from an international comparative study. Am J Kidney Dis. 2000;35(1):157\u201365.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"1106_CR4","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1111\/j.1742-1241.2009.02038.x","volume":"63","author":"J Cheng","year":"2009","unstructured":"Cheng J, Zhang W, Zhang XH, He Q, Tao XJ, Chen JH. ACEI\/ARB therapy for IgA nephropathy: a meta analysis of randomised controlled trials. Int J Clin Pract. 2009;63(6):880\u20138.","journal-title":"Int J Clin Pract"},{"issue":"8","key":"1106_CR5","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/ki.2012.280","volume":"82","author":"J Radhakrishnan","year":"2012","unstructured":"Radhakrishnan J, Cattran DC. The KDIGO practice guideline on glomerulonephritis: reading between the (guide)lines\u2013application to the individual patient. Kidney Int. 2012;82(8):840\u201356.","journal-title":"Kidney Int"},{"issue":"5","key":"1106_CR6","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG, Jardine MJ, Hladunewich M, Jha V, et al. Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the testing randomized clinical trial. JAMA. 2017;318(5):432\u201342.","journal-title":"JAMA"},{"issue":"25","key":"1106_CR7","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368(25):2402\u201314.","journal-title":"N Engl J Med"},{"issue":"1","key":"1106_CR8","doi-asserted-by":"publisher","first-page":"288","DOI":"10.1186\/s12885-019-5490-y","volume":"19","author":"J Ying","year":"2019","unstructured":"Ying J, Zhou D, Gu T, Huang J, Liu H. Pretreatment albumin\/fibrinogen ratio as a promising predictor for the survival of advanced non small-cell lung cancer patients undergoing first-line platinum-based chemotherapy. BMC Cancer. 2019;19(1):288.","journal-title":"BMC Cancer"},{"issue":"11","key":"1106_CR9","doi-asserted-by":"publisher","first-page":"2788","DOI":"10.1007\/s00268-017-4074-8","volume":"41","author":"S Matsuda","year":"2017","unstructured":"Matsuda S, Takeuchi H, Kawakubo H, Fukuda K, Nakamura R, Suda K, et al. Prognostic impact of change in the fibrinogen and albumin score during preoperative treatment in esophageal cancer patients. World J Surg. 2017;41(11):2788\u201395.","journal-title":"World J Surg"},{"issue":"1","key":"1106_CR10","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1097\/01.ASN.0000103869.08096.4F","volume":"15","author":"C Pozzi","year":"2004","unstructured":"Pozzi C, Andrulli S, Del Vecchio L, Melis P, Fogazzi GB, Altieri P, et al. Corticosteroid effectiveness in IgA nephropathy: long-term results of a randomized, controlled trial. J Am Soc Nephrol. 2004;15(1):157\u201363.","journal-title":"J Am Soc Nephrol"},{"issue":"9","key":"1106_CR11","doi-asserted-by":"publisher","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","volume":"150","author":"AS Levey","year":"2009","unstructured":"Levey AS, Stevens LA, Schmid CH, Zhang YL, Castro AF 3rd, Feldman HI, et al. A new equation to estimate glomerular filtration rate. Ann Intern Med. 2009;150(9):604\u201312.","journal-title":"Ann Intern Med"},{"issue":"5","key":"1106_CR12","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1038\/ki.2009.243","volume":"76","author":"DC Cattran","year":"2009","unstructured":"Working Group of the International Ig ANN, the Renal Pathology S, Cattran DC, Coppo R, Cook HT, Feehally J, et al. The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification. Kidney Int. 2009;76(5):534\u201345.","journal-title":"Kidney Int"},{"issue":"5","key":"1106_CR13","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC, Cook HT, Coppo R, Haas M, et al. Oxford classification of IgA nephropathy 2016: an update from the IgA nephropathy classification working group. Kidney Int. 2017;91(5):1014\u201321.","journal-title":"Kidney Int"},{"issue":"1","key":"1106_CR14","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1186\/s12882-019-1420-0","volume":"20","author":"TD Bi","year":"2019","unstructured":"Bi TD, Zheng JN, Zhang JX, Yang LS, Liu N, Yao L, et al. Serum complement C4 is an important prognostic factor for IgA nephropathy: a retrospective study. BMC Nephrol. 2019;20(1):244.","journal-title":"BMC Nephrol"},{"issue":"3","key":"1106_CR15","doi-asserted-by":"publisher","first-page":"484","DOI":"10.2215\/CJN.01990213","volume":"9","author":"X Li","year":"2014","unstructured":"Li X, Liu Y, Lv J, Shi S, Liu L, Chen Y, et al. Progression of IgA nephropathy under current therapy regimen in a Chinese population. Clin J Am Soc Nephrol. 2014;9(3):484\u20139.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"6","key":"1106_CR16","doi-asserted-by":"publisher","first-page":"e38904","DOI":"10.1371\/journal.pone.0038904","volume":"7","author":"J Xie","year":"2012","unstructured":"Xie J, Kiryluk K, Wang W, Wang Z, Guo S, Shen P, et al. Predicting progression of IgA nephropathy: new clinical progression risk score. PLoS ONE. 2012;7(6):e38904.","journal-title":"PLoS ONE"},{"key":"1106_CR17","unstructured":"Kidney Disease: Improving Global Outcomes Glomerular Diseases Work G. KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Int. 2021, 100(4S): S1-S276."},{"issue":"12","key":"1106_CR18","doi-asserted-by":"publisher","first-page":"3694","DOI":"10.1093\/ndt\/gfp356","volume":"24","author":"C Manno","year":"2009","unstructured":"Manno C, Torres DD, Rossini M, Pesce F, Schena FP. Randomized controlled clinical trial of corticosteroids plus ACE-inhibitors with long-term follow-up in proteinuric IgA nephropathy. Nephrol Dial Transplant. 2009;24(12):3694\u2013701.","journal-title":"Nephrol Dial Transplant"},{"issue":"2","key":"1106_CR19","first-page":"1234","volume":"17","author":"Y Hao","year":"2019","unstructured":"Hao Y, Zhao Y, Huang R, Fu P. Analysis of the relationship between Oxford classification, IgM deposition and multiple indexes and the adverse prognosis of patients with primary IgA nephropathy and related risk factors. Exp Ther Med. 2019;17(2):1234\u20139.","journal-title":"Exp Ther Med"},{"key":"1106_CR20","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.intimp.2018.10.044","volume":"66","author":"D Liu","year":"2019","unstructured":"Liu D, You J, Liu Y, Tang X, Tan X, Xia M, et al. Serum immunoglobulin G provides early risk prediction in immunoglobulin a nephropathy. Int Immunopharmacol. 2019;66:13\u20138.","journal-title":"Int Immunopharmacol"},{"issue":"5","key":"1106_CR21","doi-asserted-by":"publisher","first-page":"744","DOI":"10.1111\/his.13803","volume":"74","author":"Y Wang","year":"2019","unstructured":"Wang Y, Hu Z, Wu J, Wang P, Yang Q, Li Y, et al. High renal DC-SIGN(+) cell density is associated with severe renal lesions and poor prognosis in patients with immunoglobulin a nephropathy. Histopathology. 2019;74(5):744\u201358.","journal-title":"Histopathology"},{"key":"1106_CR22","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1186\/s12986-018-0328-1","volume":"16","author":"FY Xia","year":"2019","unstructured":"Xia FY, Zhu L, Xu C, Wu QQ, Chen WJ, Zeng R, et al. Plasma acylcarnitines could predict prognosis and evaluate treatment of IgA nephropathy. Nutr Metab. 2019;16:2.","journal-title":"Nutr Metab"},{"key":"1106_CR23","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1186\/s12967-015-0549-2","volume":"13","author":"Y Yuan","year":"2015","unstructured":"Yuan Y, Wang Q, Ni Z, Che X, Cao L, Shao X, et al. Long-term kidney survival analyses in IgA nephropathy patients under steroids therapy: a case control study. J Transl Med. 2015;13:186.","journal-title":"J Transl Med"},{"key":"1106_CR24","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1186\/1479-5876-12-194","volume":"12","author":"Z Ni","year":"2014","unstructured":"Ni Z, Yuan Y, Wang Q, Cao L, Che X, Zhang M, et al. Time-averaged albumin predicts the long-term prognosis of IgA nephropathy patients who achieved remission. J Transl Med. 2014;12:194.","journal-title":"J Transl Med"},{"issue":"4","key":"1106_CR25","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1093\/ndt\/gfr527","volume":"27","author":"W Le","year":"2012","unstructured":"Le W, Liang S, Hu Y, Deng K, Bao H, Zeng C, et al. Long-term renal survival and related risk factors in patients with IgA nephropathy: results from a cohort of 1155 cases in a Chinese adult population. Nephrol Dial Transplant. 2012;27(4):1479\u201385.","journal-title":"Nephrol Dial Transplant"},{"issue":"4","key":"1106_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1007\/s10157-012-0744-x","volume":"17","author":"K Hirano","year":"2013","unstructured":"Hirano K, Kawamura T, Tsuboi N, Okonogi H, Miyazaki Y, Ikeda M, et al. The predictive value of attenuated proteinuria at 1 year after steroid therapy for renal survival in patients with IgA nephropathy. Clin Exp Nephrol. 2013;17(4):555\u201362.","journal-title":"Clin Exp Nephrol"},{"issue":"4","key":"1106_CR27","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1111\/bju.13414","volume":"118","author":"J Obata","year":"2016","unstructured":"Obata J, Tanaka N, Mizuno R, Kanao K, Mikami S, Matsumoto K, et al. Plasma fibrinogen level: an independent prognostic factor for disease-free survival and cancer-specific survival in patients with localised renal cell carcinoma. BJU Int. 2016;118(4):598\u2013603.","journal-title":"BJU Int"},{"key":"1106_CR28","first-page":"145561320920746","volume":"100","author":"H Cai","year":"2020","unstructured":"Cai H, Zhang ZH, Zhou YJ, Liu J, Chen HQ, Lin RY. The prognostic value of preoperative plasma fibrinogen and neutrophil-to-lymphocyte ratio in patients with laryngeal squamous cell carcinoma. Ear Nose Throat J. 2020;100:145561320920746.","journal-title":"Ear Nose Throat J"},{"key":"1106_CR29","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.humpath.2018.01.026","volume":"75","author":"M Pan","year":"2018","unstructured":"Pan M, Zhang J, You X, Li D, Lv Y, Zhang J, et al. Renal outcomes in primary IgA nephropathy patients with segmental glomerular necrosis: a case-control study. Hum Pathol. 2018;75:47\u201354.","journal-title":"Hum Pathol"},{"issue":"23","key":"1106_CR30","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C, Sommerer C, Zeier M, Otte B, et al. Intensive supportive care plus immunosuppression in IgA nephropathy. N Engl J Med. 2015;373(23):2225\u201336.","journal-title":"N Engl J Med"},{"issue":"4","key":"1106_CR31","doi-asserted-by":"publisher","first-page":"1044","DOI":"10.1016\/j.kint.2020.04.046","volume":"98","author":"T Rauen","year":"2020","unstructured":"Rauen T, Wied S, Fitzner C, Eitner F, Sommerer C, Zeier M, et al. After ten years of follow-up, no difference between supportive care plus immunosuppression and supportive care alone in IgA nephropathy. Kidney Int. 2020;98(4):1044\u201352.","journal-title":"Kidney Int"},{"issue":"1","key":"1106_CR32","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/ASN.2017060713","volume":"29","author":"T Rauen","year":"2018","unstructured":"Rauen T, Fitzner C, Eitner F, Sommerer C, Zeier M, Otte B, et al. Effects of two immunosuppressive treatment protocols for IgA nephropathy. J Am Soc Nephrol. 2018;29(1):317\u201325.","journal-title":"J Am Soc Nephrol"},{"key":"1106_CR33","doi-asserted-by":"publisher","first-page":"715253","DOI":"10.3389\/fphar.2021.715253","volume":"12","author":"X Huang","year":"2021","unstructured":"Huang X, Xu G. An update on targeted treatment of IgA nephropathy: an autoimmune perspective. Front Pharmacol. 2021;12:715253.","journal-title":"Front Pharmacol"}],"container-title":["European Journal of Medical Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40001-023-01106-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40001-023-01106-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,3]],"date-time":"2023-04-03T10:44:23Z","timestamp":1680518663000},"score":1,"resource":{"primary":{"URL":"https:\/\/eurjmedres.biomedcentral.com\/articles\/10.1186\/s40001-023-01106-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,3]]},"references-count":33,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1106"],"URL":"https:\/\/doi.org\/10.1186\/s40001-023-01106-6","relation":{},"ISSN":["2047-783X"],"issn-type":[{"value":"2047-783X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,3]]},"assertion":[{"value":"18 December 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 April 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was performed in accordance with the Declaration of Helsinki. This study was approved by the Medical Institutional Ethics Committee of Taizhou People\u2019s Hospital, The Affiliated Hospital of Nanjing Medical University. Each enrolled participant was required to offer signed informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"146"}}